کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6151147 | 1231506 | 2014 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Rationale and design of a multicenter randomized clinical trial with memantine and dextromethorphan in ketamine-responder patients
ترجمه فارسی عنوان
مبانی و طراحی یک کارآزمایی بالینی تصادفی چند ساله با مهمانتین و دکسترومتورفان در بیماران مبتلا به کتامین
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
NMDASF 36Short Form 36 Health SurveyRTIGNTNPRSPGICBPIBLCN-methyl-d-aspartateDN4Stockings of CambridgeNSAIDSQuality of life - کیفیت زندگیMAOIs - MAOI هاNMDA receptor - NMDA گیرندهIST - استPatient Global Impression of Change - تجربیات جهانی بیمار از تغییرanalysis of variance - تحلیل واریانسANOVA - تحلیل واریانس Analysis of varianceNon-steroidal anti-inflammatory drugs - داروهای ضد التهابی غیر استروئیدیHAD - داشته استNeuropathic pain - درد نوروپاتیکDextromethorphan - دکسترومتورفانreaction time - زمان واکنشSOC - سیستم روی یک تراشهbrief pain inventory - فهرست کم دردNumeric Pain Rating Scale - مقیاس درجه بندی درد عددیMemantine - ممانتین Monoamine oxidase inhibitors - مهار کننده های مونوآمین اکسیدازNeuropathic pain symptom inventory - موجودی علامت درد نوروپاتیکKetamine - کتامین
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
پزشکی و دندانپزشکی (عمومی)
چکیده انگلیسی
The N-methyl-d-aspartate receptor plays an important role in central sensitization of neuropathic pain and N-methyl-d-aspartate receptor antagonists, such as ketamine, memantine and dextromethorphan may be used for persistent pain. However, ketamine cannot be repeated too often because of its adverse events. A drug relay would be helpful in the outpatient to postpone or even cancel the next ketamine infusion. This clinical trial evaluates if memantine and/or dextromethorphan given as a relay to ketamine responders may maintain or induce a decrease of pain intensity and have a beneficial impact on cognition and quality of life. This trial is a multi-center, randomized, controlled and single-blind clinical study (NCT01602185). It includes 60 ketamine responder patients suffering from neuropathic pain. They are randomly allocated to memantine, dextromethorphan or placebo. After ketamine infusion, 60 patients received either memantine (maximal dose 20 mg/day), or dextromethorphan (maximal dose 90 mg/day), or placebo for 12 weeks. The primary endpoint is pain measured on a (0-10) Numeric Rating Scale 1 month after inclusion. Secondary outcomes include assessment of neuropathic pain, sleep, quality of life, anxiety/depression and cognitive function at 2 and 3 months. Data analysis is performed using mixed models and the tests are two-sided, with a type I error set at α = 0.05. This study will explore if oral memantine and/or dextromethorphan may be a beneficial relay in ketamine responders and may diminish ketamine infusion frequency. Preservation of cognitive function and quality of life is also a central issue that will be analyzed in these vulnerable patients.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Contemporary Clinical Trials - Volume 38, Issue 2, July 2014, Pages 314-320
Journal: Contemporary Clinical Trials - Volume 38, Issue 2, July 2014, Pages 314-320
نویسندگان
Gisèle Pickering, Bruno Pereira, Véronique Morel, Florence Tiberghien, Elodie Martin, Fabienne Marcaillou, Pascale Picard, Noémie Delage, Géraldine de Montgazon, Marc Sorel, Delphine Roux, Claude Dubray,